MediciNova (MNOV) BidaskScore is downgraded to Sold


The BidaskScore of MediciNova MNOVMNOV shows that the shares of the company are now MNOVStrongly Bought Sold by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Sold since January 4.

Here are the BidAskScore of other related companies in the Biotechnology sector:

MediciNovaˌ Inc. operates as a biopharmaceutical company with interest in acquiring and developing novelˌ small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. The companyʿs development pipeline consists of product development programs which have been in clinical development for the treatment of acute exacerbations of asthmaˌ chronic obstructive pulmonary disease exacerbationsˌ multiple sclerosis and other neurologic conditionsˌ asthmaˌ interstitial cystitisˌ solid tumor cancersˌ generalized anxiety disorderˌ preterm labor and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova was founded by Yuichi Iwaki on September 26ˌ 2000 and is headquartered in San Diegoˌ CA.


Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.